“D” is for Diagnosis: The Radiologist’s Role in Detecting and Diagnosing Rare Interstitial Lung Diseases

Released On
September 16, 2020

Expires On
September 16, 2021

Media Type

Completion Time
60 minutes

Pulmonology, Radiology

Pulmonary Fibrosis, Radiology, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)
  • Nurses — 1.00 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward radiologists, pulmonologists, pathologists, physician assistants, nurse practitioners, and additional health care professionals who are involved in the diagnosis of ILDs.

Activity Overview

Interstitial lung diseases (ILDs) comprise a large group of lung disorders with similar clinical, physiologic, pathologic, and radiologic characteristics. In progressive or severe forms, ILDs lead to loss of lung function, respiratory failure, decreased quality of life, and early mortality. Although considered rare, the incidence has increased for both ILDs of unknown cause and those associated with other diseases or environmental exposures. Disease classification is also expanding and becoming more complex.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the “D” is for Diagnosis: The Radiologist’s Role in Detecting and Diagnosing Rare Interstitial Lung Diseases program that was held in August 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of diagnosing patients with ILDs, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the pathophysiology of multiple ILD subtypes and how these mechanisms influence diagnostic signs, symptoms, and radiologic findings
  • Interpret radiographic patterns on high-resolution computed tomography (HRCT) to differentially diagnose ILDs
  • Evaluate efficacy and tolerability of new and emerging treatments for ILD subtypes and potential use in clinical practice


Ami N. Rubinowitz, MD

Associate Professor of Radiology and Biomedical Imaging
Memorial Sloan-Kettering Cancer Center (MSKCC)
Yale School of Medicine
Yale New Haven Hospital
New Haven, CT

Jonathan H. Chung, MD

Professor of Radiology
Vice Chair of Quality
Section Chief of Cardiopulmonary Imaging
The University of Chicago Medicine
Chicago, IL

Michael A. Kadoch, MD

Cardiothoracic Radiologist
Sutter Health
Sacramento, CA

Lisa H. Lancaster, MD

Associate Professor of Medicine
Medical Director of the Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN

Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Ami N. Rubinowitz, MD, has no relevant financial relationships with commercial interest to disclose

Jonathan H. Chung, MD, has no relevant financial relationships with commercial interest to disclose.

Michael A. Kadoch, MD, has no relevant financial relationships with commercial interest to disclose.

Lisa H. Lancaster, MD

  • Grant Research Support: Bellerophon Therapeutics, Novartis, Celgene, Galecto, Respirant Pharma, Biogen, Bristol Myers Squibb, Boehringer Ingelheim, FibroGen, Galapagos NV, Piront
  • Consultant: Galapagos NV, United Therapeutics, Bristol Myers Squibb
  • Speakers Bureau: Genentech, Boehringer Ingelheim
  • Other: Spouse is an employee of Medtronic

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation/How to Receive Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.